Financial Data and Key Metrics Changes - iRhythm reported Q4 2025 revenue of $208.9 million, representing a 27.1% year-over-year growth, and full year 2025 revenue of $747.1 million, reflecting a 26.2% growth compared to 2024 [19][20] - The company achieved its first positive net income in Q4 2025, amounting to $5.6 million, or $0.17 per diluted share, while the full year net loss was $44.6 million, or a loss of $1.39 per diluted share [22] - Adjusted EBITDA for Q4 was $34.3 million, or 16.4% of revenue, marking a 470 basis point improvement year-over-year, and full year adjusted EBITDA was $68.9 million, or 9.2% of revenue, an improvement of over 1,000 basis points compared to 2024 [23] Business Line Data and Key Metrics Changes - The growth in Q4 was primarily driven by sustained volume demand across customer bases, with new store growth accounting for approximately 68% of year-over-year volume growth [20][21] - The Zio AT offering performed exceptionally well, with unit growth running more than twice the company average for the year [12][13] - The company holds approximately 15% market share in the MCT market, compared to 72% in long-term cardiac monitoring [14] Market Data and Key Metrics Changes - iRhythm serves approximately 40,000 primary care physicians, with more than one-third of volume originating from primary care settings [9] - The company is now commercial in the U.K., select E.U. markets, and Japan, where it holds less than 1% market share, indicating significant growth potential [14][15] - The U.K. market saw the largest quarter of volume ever for iRhythm, and the company is participating in NHS pilots [14] Company Strategy and Development Direction - iRhythm aims to shift from episodic detection to proactive, integrated, and predictive care, addressing the need for long-term continuous monitoring [8] - The company plans to focus on durable, volume-led growth across cardiology, primary care, and innovative channels, while expanding margins through operational efficiencies [16] - The strategic direction includes advancing platform innovation, scaling international markets, and maintaining operational excellence [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver durable growth while expanding profitability, emphasizing the importance of addressing rising clinical needs and constrained access in healthcare [28][29] - The company anticipates revenue for 2026 to be in the range of $870 million-$880 million, representing 16%-18% year-over-year growth [24] - Management highlighted the importance of integrating EHR systems and predictive AI capabilities to enhance patient care and operational efficiency [10][11] Other Important Information - 2025 marked the first year of positive adjusted EBITDA and free cash flow in the company's history, demonstrating profitable growth [23][24] - The company is actively working on a next-generation MCT device, expected to be released in the first half of 2027, which will feature a 21-day wear time and enhanced algorithms [13][56] - iRhythm is positioned at the intersection of several trends, including an aging population and increasing demand for proactive health management [15] Q&A Session Summary Question: Concerns about the elimination of chart-derived diagnosis from CMS - Management addressed concerns by stating that Zio provides confirmatory diagnoses, which is crucial for integration into patient records and audit processes [32][33] Question: Guidance on gross and operating margins for 2026 - Management provided guidance for adjusted EBITDA margin of 11.5%-12.5% for 2026 and expected gross margin improvement of 80-100 basis points relative to 2025 [37] Question: Potential tailwind from CMS proposals regarding chart scraping - Management indicated that the confirmatory diagnosis provided by Zio could serve as a tailwind, as partners are focused on improving documentation and reducing costs [40][41] Question: International growth assumptions for 2026 - Management expects international growth to slightly exceed overall company growth, with significant potential in newly opened markets [43] Question: AI concerns and billing implications - Management expressed confidence in their closed platform and the quality of data, emphasizing that AI capabilities must fit within existing workflows [48][49] Question: Updates on the MCT product timeline and enhancements - Management confirmed that the MCT product is on track for a first half 2027 release, with significant enhancements including a mobile gateway and improved algorithms [55][56]

Financial Data and Key Metrics Changes - iRhythm reported Q4 2025 revenue of $208.9 million, representing a 27.1% year-over-year growth, and full year 2025 revenue of $747.1 million, reflecting a 26.2% growth compared to 2024 [19][20] - Gross margin for Q4 was 70.9%, an increase of 90 basis points year-over-year, while full year gross margin was 70.6%, an improvement of 170 basis points year-over-year [21] - The company achieved its first positive net income in Q4 2025, amounting to $5.6 million, or $0.17 per diluted share, while the full year net loss was $44.6 million, or a loss of $1.39 per diluted share [22] - Adjusted EBITDA for Q4 was $34.3 million, or 16.4% of revenue, marking a 470 basis point improvement year-over-year, and full year adjusted EBITDA was $68.9 million, or 9.2% of revenue, representing an improvement of over 1,000 basis points compared to 2024 [23][24] Business Line Data and Key Metrics Changes - The growth in Q4 was driven by sustained volume demand across all channels, with new store growth accounting for approximately 68% of year-over-year volume growth [20] - The Zio AT offering performed exceptionally well, with unit growth running more than twice the company average for the year [12][14] - The company serves approximately 40,000 primary care physicians, with more than one-third of volume originating in primary care settings [9] Market Data and Key Metrics Changes - iRhythm holds a 72% market share in long-term continuous monitoring, with the segment growing in the high teens [7] - International markets represent a significant growth opportunity, with the company now commercial in the U.K., select E.U. markets, and Japan, where it holds less than 1% market share [14][15] - The U.K. delivered the largest quarter of volume ever for iRhythm, and the company is participating in pilots under the NHS Supply Chain's value-based procurement program [14] Company Strategy and Development Direction - The company aims to shift from episodic detection to proactive, integrated, and increasingly predictive care, addressing the need for long-term continuous monitoring [8] - iRhythm's strategy includes expanding margins through operational efficiencies, advancing platform innovation, and scaling international and adjacent markets [16] - The company is focused on delivering durable, volume-led growth across cardiology, primary care, and innovative channels while maintaining operational excellence [16][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver another year of durable, volume-led growth while expanding profitability [29] - The company is well-positioned to lead market expansion, driven by trends such as an aging population and increasing prevalence of arrhythmias [15][16] - Management highlighted the importance of confirmatory diagnoses in the context of recent regulatory scrutiny and expressed optimism about the potential tailwinds from these changes [17][41] Other Important Information - 2026 marks iRhythm's twentieth anniversary, with a goal to become a billion-dollar company by 2027 [18] - The company expects revenue for full year 2026 to be in the range of $870 million-$880 million, representing 16%-18% year-over-year growth [24][25] Q&A Session Summary Question: Concerns about the elimination of chart-derived diagnosis from CMS - Management addressed concerns by emphasizing that Zio provides confirmatory diagnoses, which is crucial for compliance and documentation [32][34] Question: Guidance on gross and operating margins for 2026 - Management provided guidance for adjusted EBITDA margin of 11.5%-12.5% for 2026 and expected gross margin improvement of 80-100 basis points relative to 2025 [37] Question: Potential tailwind from CMS proposals regarding chart scraping - Management indicated that the confirmatory diagnosis aspect of Zio could serve as a tailwind, although no specific assumptions were factored into forward-looking expectations [40][41] Question: AI concerns and potential impact on billing - Management expressed confidence in their unique data and regulatory position, stating that their platform's closed nature and established workflows would mitigate risks associated with AI adoption [48][49] Question: Updates on MCT product timeline and features - Management confirmed that the next-generation MCT device is expected to launch in the first half of 2027, featuring a mobile gateway and enhanced algorithms [56][57] Question: Guidance on international growth for 2026 - Management indicated that international growth is expected to slightly outpace overall company growth, with significant potential in newly opened markets [43]

Financial Data and Key Metrics Changes - iRhythm reported Q4 2025 revenue of $208.9 million, a 27.1% year-over-year growth, and full year 2025 revenue of $747.1 million, reflecting a 26.2% increase compared to 2024 [17][18] - Gross margin for Q4 was 70.9%, up 90 basis points year-over-year, while full year gross margin was 70.6%, an improvement of 170 basis points [18] - The company achieved its first positive net income in Q4 2025, amounting to $5.6 million, or $0.17 per diluted share, while the full year net loss was $44.6 million [19] - Adjusted EBITDA for Q4 was $34.3 million, representing 16.4% of revenue, and for the full year, it was $68.9 million, or 9.2% of revenue, marking a significant improvement [20] Business Line Data and Key Metrics Changes - Growth in Q4 was driven by sustained volume demand across all channels, with new store growth accounting for approximately 68% of year-over-year volume growth [17][18] - The Zio AT offering performed exceptionally well, with unit growth running more than twice the company average for the year [10][11] - The company holds a 15% market share in the MCT market, compared to a 72% share in long-term cardiac monitoring [12] Market Data and Key Metrics Changes - iRhythm serves approximately 40,000 primary care physicians, with more than one-third of volume originating from primary care settings [8] - The company is now commercial in the U.K., select E.U. markets, and Japan, where it holds less than 1% market share [12] - In the U.K., iRhythm delivered its largest quarter of volume ever and is participating in NHS pilots [12] Company Strategy and Development Direction - The company aims to shift from episodic detection to proactive, integrated, and predictive care, addressing the growing need for long-term continuous monitoring [7][14] - iRhythm's strategy includes expanding margins through operational efficiencies, advancing platform innovation, and scaling international markets [14][26] - The company is focused on maintaining operational excellence and compliance in a rapidly evolving healthcare environment [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver durable, volume-led growth while expanding profitability in 2026 [26] - The company anticipates revenue for 2026 to be in the range of $870 million to $880 million, representing 16%-18% year-over-year growth [21] - Management highlighted the importance of addressing the challenges in arrhythmia detection and the need for proactive care models [25] Other Important Information - 2025 marked the first year of positive adjusted EBITDA and free cash flow in the company's history [20][21] - The company is actively working on its next-generation MCT device, which is currently under FDA review and expected to be released in the first half of 2027 [11][12] Q&A Session Summary Question: Concerns about chart-derived diagnosis elimination from CMS - Management addressed concerns about chart-derived diagnosis, emphasizing that Zio provides confirmatory diagnoses, which is crucial for integration into workflows and patient records [30][31] Question: Guidance on gross and operating margins for 2026 - Management provided guidance for adjusted EBITDA margin of 11.5%-12.5% for 2026 and expected gross margin improvement of 80-100 basis points relative to 2025 [35][37] Question: Potential tailwind from CMS proposal regarding chart scraping - Management indicated that the confirmatory diagnosis from Zio could serve as a tailwind, as providers seek to bolster documentation in patient records [39][40] Question: AI concerns and customer willingness to perform analysis - Management expressed confidence in their unique data and regulatory position, stating that their platform's closed nature and established workflows would protect against potential AI competition [45][46] Question: Updates on MCT product timeline and enhancements - Management confirmed confidence in the MCT product's timeline for the first half of 2027, highlighting necessary enhancements and the transition to a mobile gateway [51][56] Question: Guidance on partnerships and their scaling - Management noted the addition of incremental partners and emphasized a cautious approach to guidance for the innovative channel business, which is still emerging [65][66]

Core Insights - iRhythm Holdings, Inc. reported strong financial results for Q4 and full year 2025, marking a transformational year with significant revenue growth and positive net income for the first time in its history [4][10]. Financial Highlights Fourth Quarter 2025 - Revenue increased by 27.1% to $208.9 million compared to $164.3 million in Q4 2024, driven by higher demand for Zio Services [5][8]. - Gross profit rose to $148.1 million, up from $115.1 million in Q4 2024, with a gross margin of 70.9%, an improvement from 70.0% [6][8]. - Net income for Q4 2025 was $5.6 million, a significant improvement from a net loss of $1.3 million in Q4 2024 [9][8]. - Adjusted EBITDA was $34.3 million, with an adjusted EBITDA margin of 16.4%, reflecting a $15.0 million increase compared to Q4 2024 [8]. Full Year 2025 - Total revenue for 2025 reached $747.1 million, a 26.2% increase from $591.8 million in 2024 [10][11]. - Gross profit for the year was $527.3 million, up from $407.5 million in 2024, with a gross margin of 70.6%, improving from 68.9% [11]. - The net loss for 2025 was $44.6 million, a $68.7 million improvement compared to a net loss of $113.3 million in 2024 [12][10]. - Free cash flow for 2025 was $34.5 million, marking the first year of positive free cash flow in the company's history [8]. Operational Highlights - The company emphasized the growing demand for Zio across various healthcare sectors, highlighting its ability to provide proactive, data-driven arrhythmia detection [4]. - iRhythm plans to scale its platform globally, advance its product roadmap, and enhance its predictive AI capabilities while maintaining financial discipline [4]. 2026 Guidance - For 2026, iRhythm expects revenue between $870 million and $880 million, with an adjusted EBITDA margin of 11.5% to 12.5%, indicating continued growth and operational efficiency [13].

iRhythm Technologies (NasdaqGS:IRTC) FY Conference Summary Company Overview - **Company**: iRhythm Technologies - **Industry**: MedTech, specifically in cardiac monitoring and arrhythmia detection - **Conference Date**: January 12, 2026 Key Points and Arguments Financial Performance - iRhythm achieved over **$740 million** in revenue for 2025, exceeding guidance and marking the first profitable year in the company's history [10][35] - The company expects **$870-$880 million** in revenue for 2026, representing a growth of **17%-18%** [35] - For the first time, iRhythm will be **free cash flow positive** in 2025, with an expected **11.5%-12.5%** adjusted EBITDA margin for 2026 [35][36] Market Opportunity - There are **27 million undiagnosed individuals** with cardiac arrhythmias in the U.S., representing a significant market opportunity [5][11] - iRhythm currently holds **72% market share** in long-term cardiac monitoring (LTCM) and aims to expand its presence in the **Mobile Cardiac Telemetry (MCT)** space, where it has only **15% market share** [13][24] - The company is targeting a **30 million test** market opportunity, including both undiagnosed patients and international markets [12][13] Product and Technology - iRhythm's **Zio** monitoring system allows patients to wear a device for **14 days**, capturing nearly **1.5 million heartbeats** [8] - The company is developing a **third-generation algorithm** for arrhythmia detection, which is currently with the FDA [9] - iRhythm is leveraging **AI** to analyze **3 billion hours** of heartbeat data, enhancing predictive capabilities for undiagnosed arrhythmias [22][27] Strategic Initiatives - The company is focusing on expanding into **primary care**, with over **20% of prescribing** now coming from this channel [17] - iRhythm is collaborating with **innovative channel partners** to target comorbid disease states, which overlap significantly with arrhythmias [20] - The company is also exploring opportunities in adjacent markets such as **sleep apnea**, where there is a high correlation with arrhythmias [32][33] Competitive Landscape - iRhythm has a competitive advantage due to its established product in LTCM, while competitors primarily focus on MCT, making it difficult for them to penetrate the primary care market [52][53] - The company has been successful in integrating with **EHR systems**, which has led to a **20%-25% increase** in volume post-integration [30] Research and Evidence Generation - iRhythm has published over **135 research manuscripts**, with nearly **40 peer-reviewed**, establishing a strong evidence base for its products [11][12] - The company emphasizes the cost savings associated with early arrhythmia detection, estimating **$15-$17 million** in savings for every **1,000 patients** identified [32] Future Outlook - iRhythm is optimistic about its growth trajectory, with plans to continue investing in technology and market expansion while maintaining profitability [36][59] - The company aims to achieve **15% adjusted EBITDA margins** as it approaches **$1 billion** in revenue [37] Additional Important Insights - The company is addressing **capacity constraints** in the healthcare system by moving monitoring to primary care, where there is a significant shortage of cardiologists [6][17] - iRhythm's proactive approach to identifying undiagnosed patients through AI and data analysis is seen as a game changer in the industry [23][27] - The company is currently working on enhancing its MCT product to meet market demands for longer monitoring durations [24][46] This summary encapsulates the key points discussed during the iRhythm Technologies FY Conference, highlighting the company's financial performance, market opportunities, product innovations, strategic initiatives, competitive landscape, and future outlook.

Summary of Krystal Biotech Conference Call Company Overview - **Company**: Krystal Biotech - **Industry**: Biotechnology, specifically focused on genetic medicines and rare diseases Key Points and Arguments Product Launch and Performance - **Vyjuvek**: Launched in September 2023 for treating Dystrophic Epidermolysis Bullosa (DEB) - First re-dosable genetic medicine and can be applied at home, which is a significant differentiation in gene therapy [3][4] - Positive patient and physician experiences reported, leading to high compliance and reimbursement approvals [4][6] - Launched in Europe (France, Germany) and Japan, with plans for further expansion in Europe [5][34] Financial Position - Krystal Biotech has achieved nearly 10 consecutive quarters of positive EPS since the launch of Vyjuvek [6] - Strong balance sheet with no immediate plans for financing, indicating financial stability [6][9] Manufacturing and Control - Two manufacturing facilities established to maintain control over critical manufacturing processes (CMC) [6][8] - Focus on in-house operations for packaging and supply chain management [8][9] Pipeline and Future Goals - Ambition to market four rare disease products by 2026, leveraging the success of Vyjuvek [9][10] - Pipeline includes: - **KB803**: Targets lesions in the eye of DEB patients, with a market potential of over $4 billion [12][14] - **KB801**: For neurotrophic keratitis, aiming for a more consistent delivery method compared to existing treatments [22][24] - **407**: For cystic fibrosis, showing promising data for delivering functional CFTR to patients [25][26] - **KB111**: For Hailey-Hailey disease, with plans for a registrational trial [27][30] Regulatory and Clinical Development - Ongoing registrational studies for KB803 and KB801, with expectations to complete enrollment by the end of the year [21][24] - Emphasis on patient-reported outcomes and innovative trial designs to enhance data collection and analysis [21][29] Market Strategy - Krystal Biotech aims to self-launch products in the U.S., EU, and Japan for rare diseases, while considering partnerships for larger indications [10][39] - The company is actively working on distribution agreements for countries where self-launch is not feasible [5][34] Insights from Global Launch - The launch of Vyjuvek has provided valuable insights into pricing and reimbursement strategies across different markets [15][34] - The company is learning from the global launch experience to refine its pipeline and market approach [15][34] Additional Important Information - The company has no royalty obligations to universities or pharmaceutical companies, allowing complete ownership of its pipeline [9] - The focus on rare diseases is driven by the company's capabilities in developing and commercializing such products [10][11] - The management team emphasizes the importance of CMC in gene therapy development, highlighting the need for robust manufacturing processes [31][32] This summary encapsulates the key points discussed during the conference call, focusing on Krystal Biotech's product launches, financial health, pipeline ambitions, and strategic market approaches.

Core Insights - iRhythm Technologies, Inc. has reported a transformative year in 2025, achieving over 25% year-over-year revenue growth and free cash flow positivity for the first time in its history [3] Operational Highlights - The company has recorded strong commercial volumes and is well-positioned for growth in 2026 with multiple catalysts, including deeper penetration in primary care and population health through AI partnerships [3] - iRhythm's clinical evidence program, including AVALON and CAMELOT publications, supports the clinical superiority of its Zio LTCM product, which is expected to expand into additional populations and care settings [3] Financial Outlook - For full year 2025, revenue is anticipated to exceed the high end of the previously stated guidance range of $740 million, driven by record revenue unit volume in Q4 2025 [7] - The company expects revenue for 2026 to be approximately $870 million to $880 million, representing a year-over-year growth of about 17% to 18%, with an adjusted EBITDA margin of approximately 11.5% to 12.5% [7] Clinical Evidence - Recent real-world evidence from over 1.4 million patients reinforces the clinical superiority of Zio LTCM, with data demonstrating consistent performance in Asian populations and validating successful at-home self-application for earlier detection in at-risk populations [7]

Financial Data and Key Metrics Changes - The company reported over 30% growth in the most recent quarter, indicating strong performance and momentum in the business [66][67] - Preliminary revenue guidance for 2026 is projected in the high teens percentage range, reflecting a thoughtful approach to setting expectations [65][66] Business Line Data and Key Metrics Changes - The long-term continuous monitoring segment, which the company pioneered, is growing at high teens percentage year over year, outpacing the overall market growth [8][19] - The company has gained one to two points of market share in the long-term continuous monitoring segment, now holding approximately 70% of that market [19][20] Market Data and Key Metrics Changes - The overall ambulatory cardiac monitoring market in the U.S. is estimated at 6.7 million tests annually, growing at mid-single digits, while the long-term continuous monitoring segment is experiencing faster growth [8][10] - The aging population is a significant tailwind for the market, with more individuals entering Medicare and increasing the risk of cardiac arrhythmias [10] Company Strategy and Development Direction - The company is focusing on expanding its presence in the primary care market, with a goal to increase the percentage of XT patches used by primary care physicians from 30% to potentially over 40% [12][14] - The company is investing in innovative channel partnerships that allow for proactive monitoring of patients, which is expected to enhance market penetration [22][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capitalize on market opportunities, particularly in the context of improving therapies and increasing consumer awareness [10][11] - The company is optimistic about its international expansion efforts, having launched into five new markets, including Japan, and expects meaningful contributions from these markets in the future [55][56] Other Important Information - The company is currently working through the FDA review process for Zio MCT, with no expected contributions to revenue in 2026 [40][41] - Recent updates indicate that Medicare reimbursement rates for long-term continuous monitoring will increase by approximately 8% next year, which is a positive outcome for the company [76] Q&A Session Summary Question: What is the current state of the ambulatory cardiac monitoring market? - The market is healthy, with the long-term continuous monitoring segment growing at high teens percentage year over year, driven by factors such as improved therapies and increased consumer awareness [8][10] Question: How is the company addressing the primary care market? - The company has seen an increase in the percentage of XT patches used by primary care physicians and believes this trend will continue to expand [12][14] Question: What is the status of the FDA submission for Zio MCT? - The company submitted Zio MCT to the FDA in September and is currently addressing comments received, with no expected revenue contribution in 2026 [40][41] Question: How is the international business progressing? - The company has launched into five new markets and is optimistic about future contributions, particularly from Japan, which is a significant market for ambulatory cardiac monitoring [55][56] Question: What is the company's approach to setting revenue guidance? - The company aims to provide thoughtful guidance based on high confidence in certain areas while leaving out less predictable factors [66][67]

Financial Performance - iRhythm's revenue for Q3 2025 reached $192.9 million, a 30.7% increase compared to $147.5 million in Q3 2024[3, 5] - Gross profit for Q3 2025 was $137.1 million, up 35.1% from $101.5 million in Q3 2024, with a gross margin of 71.1%, a 230-basis point increase[6] - Net loss for Q3 2025 was $5.2 million, or a diluted loss of $0.16 per share, compared to a net loss of $46.2 million, or a diluted loss of $1.48 per share, in Q3 2024[8] - Adjusted EBITDA for Q3 2025 was $21.559 million, compared to $(19.886) million for Q3 2024[25] - Unrestricted cash, cash equivalents, and marketable securities totaled $565.2 million as of September 30, 2025[3, 9] Future Outlook - iRhythm projects full-year 2025 revenue between $735 million and $740 million[11] - The company anticipates an adjusted EBITDA margin for full-year 2025 ranging from approximately 8.25% to 8.75% of revenues[3, 11]

iRhythm (NasdaqGS:IRTC) 2025 Conference Summary Company Overview - **Company**: iRhythm Technologies, Inc. - **Industry**: Medical Technology, specifically in cardiac monitoring Key Points and Arguments Business Performance - iRhythm has experienced significant momentum in its core business, with the second quarter showing substantial outperformance compared to expectations, marking one of the best quarters in five years excluding COVID impacts [3][4] - The outperformance is attributed to onboarding new accounts and increasing average volume per new account, particularly through converting entire networks at once rather than in stages [4][5] Clinical Data and Competitive Advantage - The company has invested in clinical data, with studies like Camelot (300,000 patients) and Avalon (400,000 patients) demonstrating that its Zio product outperforms competitors in terms of faster diagnosis, higher diagnostic yield, and lower healthcare costs [6][7] - The strategy includes expanding from cardiology and electrophysiology (EP) into primary care, which is seeing rapid growth in prescribing rates [8][10] Market Potential - The total addressable market is estimated at 27 million undiagnosed patients with cardiac arrhythmias, significantly larger than the current 6.5 million ambulatory cardiac monitoring tests performed annually in the U.S. [11][19] - The company aims to leverage primary care to identify and treat patients earlier in their care journey, which is expected to increase the volume of patients monitored [19][20] Innovative Channels and AI Integration - iRhythm is exploring innovative channels and AI to identify patients likely to have arrhythmias, achieving a diagnostic yield of approximately 92% in pilot studies [21][22] - The company is developing algorithms to integrate with electronic medical records (EMR) to flag potential arrhythmia patients, which could enhance patient identification and reduce emergency room visits [22][25] Product Development and Regulatory Engagement - The Zio MCT product is expected to launch in the second half of 2026, with a 21-day wear period, which is anticipated to capture market share from competitors [44][46] - The relationship with the FDA has improved significantly, allowing for more collaborative discussions regarding product development and regulatory submissions [47][49] Financial Outlook - iRhythm aims for a compound annual growth rate (CAGR) of 20% through 2027, with potential for higher growth based on recent performance and market opportunities [13][14] - The company is targeting a path to 15% adjusted EBITDA margins by 2027, with potential to reach mid-20s margins through operational efficiencies, particularly in general and administrative expenses [55][57] Strategic Partnerships - Currently, iRhythm has 12 partners under contract, covering approximately 2 million lives, with an additional 40 partners in the pipeline [36][37] - The pricing model for patches is between $250 to $300, translating to a potential annual revenue opportunity of $450 to $600 million [36] Additional Important Insights - The company is focused on transitioning to a direct-to-consumer model in the future, allowing patients to access Zio products more easily [27][28] - iRhythm is committed to improving its operational capacity, with plans to increase production from 4 million to 10 million units annually [40][41] - The company recognizes the importance of addressing the high costs associated with emergency room visits for undiagnosed arrhythmia patients, positioning its products as a cost-saving solution for payers [32][25] This summary encapsulates the key insights from the iRhythm conference, highlighting the company's growth strategies, market potential, and financial outlook.